You can buy or sell Merus and other stocks, options, ETFs, and crypto commission-free!
Merus N.V. Common Shares, also called Merus, is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Read More Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
52 Week High
52 Week Low
Seeking AlphaMar 11
IBI Research On Merus: Elucidating The Prospects Of An Antibody Innovator
I share with readers my forecasting of the aforementioned trial and what you can expect from this oncology-drug innovator. The lead molecule, MCLA-128, is most advanced in the pipeline. It has substantial prospects for the management of aggressive cancers. I remember my sense of shock some half-dozen years ago when I read a recommendation to sell shares of a company. The recommendation was not based on any long-term fundamentals. Rather, it was that over the next six months the funds could be employed mor...
NASDAQ:MRUS - Stock Price, News, & Analysis for Merus
Headlines about MRUS stock have been trending somewhat positive on Monday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Merus earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 ou...
Expected Apr 25, After Hours